1. American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 15: 2996–3018
2. Bennouna J, Fumoleau P, Armand JP, Raymond E, Campone M, Delgado FM, Puozzo C, Marty ML (2003) Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours Ann. Ann Oncol 14: 630–637
3. Biesma B, Smit EF, Postmus PE (1999) A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small-cell lung cancer after platinum containing chemotherapy. Lung Cancer 24: 115–121
4. Dancey J, Shepherd F, Ramlau R, Mattson K, Gressot L, O'Rourke M, Vincent M, Burkes R, Levitan N, Bergman B, Baez L, Rudd R, Kim Y, Coughlin S, Soussan-Lazard K, Gralla R (1999) Quality of life (QOL) assessment in a randomised study of taxotere (TAX) vs best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum based chemotherapy. Proc Am Soc Clin Oncol 18: 491 (abstract 1896)
5. Etiévant C, Kruczynski A, Chansard N, Cabrol N, Astruc J, Chazottes E, Hill BTL (1998) Characterization of apoptosis induced by vinflunine, a novel fluorinated vinca alkaloid, in sensitive and vinflunine resistant P388 tumor cells: concomitant cell cycle analysis. Proc Am Assoc Cancer Res 39: 166